Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Current Opinion in Hematology

Volumn 18, Issue 6, 2011, Pages 381-387

  Dominietto, Alida ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

allogeneic hematopoietic stem cell transplant; leukemia relapse; minimal residual disease

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; GENE PRODUCT; ISOCITRATE DEHYDROGENASE (NADP); MIXED LINEAGE LEUKEMIA PROTEIN; MOLECULAR MARKER; NUCLEOPHOSMIN; ONCOPROTEIN; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FLOW CYTOMETRY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; MARKER GENE; MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW CYTOMETRY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

FLOW CYTOMETRY; GENETIC MARKERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054717409     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32834bac7d     Document Type: Review

References (50)

1. Foran JM. New prognostic markers in acute myeloid leukemia: Perspective from the clinic. Hematol Am Soc Hematol Educ Program 2010; 47-55.
2. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354-365.
3. Pavletic SZ, Kumar S, Mohty M, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic StemCell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 2010; 16:871-890.
4. Elorza I, Palacio C, Dapena JL, et al. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica 2010; 95:936-941.
5. Bishop MR, Alyea EP 3rd, Cairo MS, et al. National Cancer Institute's First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Summary and recommendations from the organizing committee. Biol Blood Marrow Transplant 2011; 17:443-454.
6. Krö ger N, Bacher U, Bader P, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010; 16:1187-1211. The first study from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following allogeneic stem cell transplantation focused on: MRD monitoring techniques, standard definitions of post-transplant remission, persistence, progression, relapse and the prediction of relapse.
7. Krö ger N, Miyamura K, Bishop MR. Minimal residual disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:S94-100.
8. Bustin S. The PCR revolution: Basic technologies and applications. Cambridge, NY: Cambridge University Press; 2009.
9. Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010; 22:656-663.
10. Dö hner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453-474.
11. Bacher U, Schnittger S, Haferlach T. Molecular genetics in acute myeloid leukemia. Curr Opin Oncol 2010; 22:646-655.
12. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352:254-266. (Pubitemid 40110814)
13. Dö hner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 2005; 106:3740-3746. (Pubitemid 41739007)
14. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:596-604.
15. Krö nke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011 [Epub ahead of print].
16. Bacher U, Badbaran A, Fehse B, et al. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 2009; 37:135-142.
17. Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006; 20:1217-1220. (Pubitemid 43905824)
18. Schnittger S, Schoch C, Kern W, et al. FLT3 length mutations as marker for follow-up studies in acute myeloid leukemia. Acta Hematol 2004; 112:68-78. (Pubitemid 38716251)
19. Dezern AE, Sung A, Kim S, et al. Role of allogeneic transplantation for FLT3/ ITD acute myeloid leukemia: Outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 2011; 17:1404-1409.
20. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909-1918. (Pubitemid 351620111)
21. Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007; 110:1262-1270. (Pubitemid 47281424)
22. Bacher U, Haferlach C, Kern W, et al. prognostic relevance of FLT3-TKD mutations in AML. The combination matters: An analysis of 3082 patients. Blood 2008; 111:2527-2537.
23. Scholl S, Loncarevic IF, Krause C, et al. Analysis of minimal residual disease based on FLT3 mutations in allogeneic peripheral blood stem cell transplantation. J Cancer Res Clin Oncol 2005; 131:279-283. (Pubitemid 40558542)
24. Marcucci G, Haferlach T, Dö hner H. Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 2011; 29:475-486. A review article focused on the most important molecular genetic abnormalities in adult AML: From biologic features to clinical significance.
25. Weisser M, Kern W, Schoch C, et al. Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 2005; 90:881-889. (Pubitemid 41024890)
26. Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011; 29:1364-1372.
27. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:2348-2355.
28. Patel KP, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: Frequency and clinicopathologic features. Am J Clin Pathol 2011; 135:35-45.
29. Dufour A, Schneider F, Metzeker KH, et al. Acute myeloid leukemia with biallelic CEPBA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010; 28:570-577.
30. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: Further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117:2469-2475.
31. Owen C, Fitzgibbon J, Paschka P. The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematol Oncol 2010; 28:13-19.
32. Paschka P, Marcucci G, Ruppert AS, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2008; 26:4595-4602.
33. Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26:5429-5435.
34. Gaidzik VI, Schlenk RF, Moschny S, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: A study of the German-Austrian AML Study Group. Blood 2009; 113:4505-4511.
35. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol 2009; 27:5195-5201.
36. Gianfaldoni G, Mannelli F, Ponziani V, et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica 2010; 95:833-836.
37. Ommen HB, Nyvold CG, Braendstrup K, et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: Development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008; 141:782-791. (Pubitemid 351724866)
38. Candoni A, Toffoletti E, Gallina R, et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant 2011; 25:308-316.
39. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101:1698-1704. (Pubitemid 36237562)
40. Dominietto A, Pozzi S, Miglino M, et al. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood 2007; 109:5063-5064. (Pubitemid 46827808)
41. Lange T, Hubmann M, Burkhardt R, et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 2011; 25:498-505.
42. Langer C, Radmacher MD, Ruppert AS, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Blood 2008; 111:5371-5379.
43. Langer C, Marcucci G, Holland KB, et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and micro- RNA expression signatures in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol 2009; 27:3198-3204.
44. Marcucci G, Maharry K, Whitman SP, et al. High expression levels of the ETSrelated gene, ERG, predict adverse outcome and improve molecular riskbased classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol 2007; 25:3337-3343. (Pubitemid 47325620)
45. Grö schel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010; 28:2101-2107.
46. Olaru D, Campos L, Flandrin P, et al. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes. Cytometry B Clin Cytom 2008; 74:17-24.
47. Arnoulet C, BénéMC, Durrieu F, et al. Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: A reference document based on a systematic approach by the GTLLF and GEIL. Cytometry B Clin Cytom 2010; 78:4-10.
48. Venditti A, Maurillo L, Buccisano F, et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 2003; 17:2178-2182. (Pubitemid 37428383)
49. Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26:4944-4951.
50. Hokland P, Ommen HB. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 2011; 117:2577-2584. The authors focused on target genes for MRD monitoring, definition of molecular relapse and showed a proposal for guidelines for the application of MRD assays in AML patients in complete remission, suggesting a patient-specific approach driven by molecular markers.